IntroductionTo analyze outcomes on objective ocular surface parameters and subjective symptoms of serial weekly sessions using the Activa mask in patients with meibomian gland dysfunction (MGD).MethodsThis is a prospective study including patients with symptomatic MGD who were treated with four weekly sessions using the Activa mask (SBM Sistemi, Turin, Italy). Noninvasive ocular surface examination was carried out before (T0) and 2 weeks after the last mask session (T1) using Idra (SBM Sistemi, Turin, Italy) for the measurement of: (1) noninvasive break-up time (NIBUT); (2) lipid layer thickness (LLT); (3) tear meniscus height (TMH); (4) meibomian gland loss (MGL) of upper and lower eyelids. The I-Pen tear osmolarity system (I-Med Pharma Inc, Dollard-des Ormeaux, Quebec, Canada) was used to measure tear osmolarity values. Ocular discomfort symptoms were ascertained by means of the ocular surface disease index (OSDI) questionnaire.ResultsAll 25 patients (11 males, 14 females; mean age 57.1 +/- 11.9 years) regularly completed the cycle of four mask sessions. No patients used prohibited medications, and no device-related adverse events were noted. At T1, mean values of NIBUT and LLT increased significantly compared to T0 (respectively from 6.0 +/- 1.4 to 6.6 +/- 1.2 s, P = 0.043, and from 53.2 +/- 17.4 to 65.3 +/- 16.3 nm, P < 0.001), while mean values of MGL and tear osmolarity decreased significantly (respectively from 17.1 +/- 9.3 to 15.1 +/- 8.0%, P = 0.014, and from 307.3 +/- 12.2 to 301.5 +/- 6.8 mOsm/l, P = 0.005). In parallel, OSDI score reduced significantly from 62.4 +/- 11.7 at T0 to 34.5 +/- 11.2 at T1 (P < 0.001).ConclusionWeekly serial sessions using the Activa mask significantly improved objective parameters of the ocular surface as well as subjective ocular discomfort symptoms in patients with recalcitrant MGD. As a further benefit from the treatment, patients were able to avoid the use of concomitant medications, apart from tear substitutes, throughout the study.
Effects of Serial Sessions of Activa Mask for the Treatment of Meibomian Gland Dysfunction
Pellegrini, Marco;D'Angelo, Sergio;
2023
Abstract
IntroductionTo analyze outcomes on objective ocular surface parameters and subjective symptoms of serial weekly sessions using the Activa mask in patients with meibomian gland dysfunction (MGD).MethodsThis is a prospective study including patients with symptomatic MGD who were treated with four weekly sessions using the Activa mask (SBM Sistemi, Turin, Italy). Noninvasive ocular surface examination was carried out before (T0) and 2 weeks after the last mask session (T1) using Idra (SBM Sistemi, Turin, Italy) for the measurement of: (1) noninvasive break-up time (NIBUT); (2) lipid layer thickness (LLT); (3) tear meniscus height (TMH); (4) meibomian gland loss (MGL) of upper and lower eyelids. The I-Pen tear osmolarity system (I-Med Pharma Inc, Dollard-des Ormeaux, Quebec, Canada) was used to measure tear osmolarity values. Ocular discomfort symptoms were ascertained by means of the ocular surface disease index (OSDI) questionnaire.ResultsAll 25 patients (11 males, 14 females; mean age 57.1 +/- 11.9 years) regularly completed the cycle of four mask sessions. No patients used prohibited medications, and no device-related adverse events were noted. At T1, mean values of NIBUT and LLT increased significantly compared to T0 (respectively from 6.0 +/- 1.4 to 6.6 +/- 1.2 s, P = 0.043, and from 53.2 +/- 17.4 to 65.3 +/- 16.3 nm, P < 0.001), while mean values of MGL and tear osmolarity decreased significantly (respectively from 17.1 +/- 9.3 to 15.1 +/- 8.0%, P = 0.014, and from 307.3 +/- 12.2 to 301.5 +/- 6.8 mOsm/l, P = 0.005). In parallel, OSDI score reduced significantly from 62.4 +/- 11.7 at T0 to 34.5 +/- 11.2 at T1 (P < 0.001).ConclusionWeekly serial sessions using the Activa mask significantly improved objective parameters of the ocular surface as well as subjective ocular discomfort symptoms in patients with recalcitrant MGD. As a further benefit from the treatment, patients were able to avoid the use of concomitant medications, apart from tear substitutes, throughout the study.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
